A graduate of the University of Montreal with a Ph.D. in Biomedical Sciences and a specialty in cardiovascular clinical research, Dr. Johnson has been involved in clinical research for almost 20 years both in private and public health organizations. She has started her career in the pharmaceutical industry where she has significantly contributed to their cardiovascular clinical research program.
In 2000, Dr. Johnson co-founded the Montreal Health Innovations Coordinating Center (MHICC), a division of the Montreal Heart Institute, an academic research organization, and has acted as its executive director for 16 years. She has been responsible for its establishment, development and growth and under her leadership, the MHICC has gained an international reputation. She has established a successful business model that supports both academic clinical research and contract research with the biopharmaceutical industry, as the presentation of the 2012 Innovation Award to MHICC by the Armand-Frappier Foundation demonstrates.
She has also sat on Steering and Operations Committees of several large international phase III multi-center cardiovascular clinical trials. Dr. Johnson has developed many partnerships within the clinical research community, including the biopharmaceutical industry, clinical research organizations, investigators and healthcare institutions.
In addition, Dr. Johnson is a faculty member of the International Partnership for Critical Markers of Disease (CMOD), supported by governmental regulatory agencies, where strategies to maximize clinical trial effectiveness are extensively discussed and where the broad goal is to create productivity toward improved patient healthcare.
Dr. Johnson has authored more than 40 publications in journals including the Journal of the American College of Cardiology, the American Heart Journal and Atherosclerosis.